This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human NKp30 / NCR3 / CD337 Protein, Fc Tag
catalog :
NC3-H5259
quantity :
100 ug, 1 mg
price :
280 USD, 1700 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
NC3-H5259
product name :
Human NKp30 / NCR3 / CD337 Protein, Fc Tag
quantity :
100 ug, 1 mg
price :
280 USD, 1700 USD
quantity & price :
$280/100ug,$1700/1mg
target :
NKp30
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
Human NKp30, Fc Tag (NC3-H5259) is expressed from human 293 cells (HEK293). It contains AA Leu 19 - Gly 135 (Accession # AAH52582).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human NKp30, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Natural cytotoxicity triggering receptor 3 (NCR3) is also known as Activating natural killer receptor p30, Natural killer cell p30-related protein (NK-p30), CD antigen CD337, 1C7, LY117. NCR3 /CD337 /NKp30 belongs to the natural cytotoxicity receptor (NCR) family. NCR3 /NKp30 contains one Ig-like (immunoglobulin-like) domain. NCR3 /NKp30 is selectively expressed by all resting and activated NK cells and weakly expressed in spleen. NCR3 is homodimer in the unliganted form. NCR3 interacts with CD3Z. NCR3 interacts with and is activated by binding to NCR3LG1 or BAG6. Engagement of NCR3 by BAG6 also promotes dendritic cell (DC) maturation, both through killing those DCs that did not properly acquire a mature phenotype, and inducing NK cells to release TNFA and IFNG, which promotes DC maturation.
References :
(1) Pende D., et al., 1999, J. Exp. Med. 190:1505-1516.
(2) Vitale M., et al., 2005, Blood 106:566-571.
(3) Simhadri V.R., et al., 2008, PLoS ONE 3:E3377-E3377.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments